Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Other Non Operating Income (2019 - 2025)

Black Diamond Therapeutics' Other Non Operating Income history spans 5 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 24.06% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $5.8 million, down 16.45%, while the annual FY2025 figure was $5.8 million, 16.45% down from the prior year.
  • Other Non Operating Income reached $1.3 million in Q4 2025 per BDTX's latest filing, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q3 2024 to a low of -$740000.0 in Q1 2021.
  • Average Other Non Operating Income over 3 years is $990363.6, with a median of $1.4 million recorded in 2024.
  • The largest YoY upside for Other Non Operating Income was 17.68% in 2021 against a maximum downside of 7300.0% in 2021.
  • A 3-year view of Other Non Operating Income shows it stood at -$489000.0 in 2021, then surged by 452.76% to $1.7 million in 2024, then fell by 24.06% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Other Non Operating Income are $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.7 million (Q2 2025).